Hundreds of people with an aggressive form of lymphoma will be able to have the first personalised immunotherapy treatment for the condition after gaining the green light from NHS regulators.
The National Institute for Health and Care Excellence (...
1 year ago
The use of reduced-dose apheresis platelet components in a severe shortage situation. 25.01.2023
Statement of Use:
It is acceptable to use a reduced-dose apheresis platelet component (specification ≥ 150 x 109/unit) instead of a standard-dose pla...
1 year ago
